Özet:

Escherichia coli ST131 isolates associated with fluoroquinolone and cephalosporin resistance have increased in the last ten years. This increase leads to the emergence of multidrug-resistant E. coli isolates and failure in the treatment of urinary tract infections. Carbapenem and fosfomycin antibiotics are among the limited treatment options for E. coli ST131 isolates. However, the increasing use of these antibiotics leads to the spread of carbapenem and fosfomycin resistance genes and increased resistance. Increasing antimicrobial resistance in Gram-negative bacteria and the scarcity of new antimicrobials have brought old antimicrobials to the agenda again. Temocillin is an old antimicrobial that has significant advantages. This agent may be an alternative to carbapenems in the treatment of serious Enterobacterales infections, such as systemic urinary tract infections. This study investigated the presence of the O25b-ST131 clone in fluoroquinolone-resistant E. coli isolates and the resistance to temocillin in these isolates. In our study, it was determined that 40.8% of the isolates were E. coli O25b-ST131 isolates. Given that all the isolates are fluoroquinolone-resistant E. coli, a high prevalence of O25b-ST131 is expected. The findings of the antibiotic resistance tests revealed that all isolates had low levels of carbapenem and fosfomycin resistance (2.04% and 3.06, respectively). Additionally, there were no significant differences in resistance between E. coli ST131 isolates and other isolates. Temocillin is an antimicrobial agent widely used in many European countries, particularly for the treatment of carbapenem-resistant E. coli infections. High rates of temocillin resistance (50%) were observed in our study, although this agent has not yet been used in our country. These high resistance rates could be related to cross-antibiotic resistance.

Anahtar Kelimeler: